SOUTH SAN FRANCISCO, CA--(Marketwire - October 15, 2007) - Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it has entered into a Committed Equity Financing Facility (CEFF) with Kingsbridge Capital Limited, a private investment group, in which Kingsbridge has committed to provide up to $75 million of capital during the next three years through the purchase of newly-issued shares of Cytokinetics' common stock. Under the terms of the agreement, Cytokinetics will determine the exact timing and amount of any CEFF financings, subject to certain conditions. The CEFF allows Cytokinetics to raise capital, at its discretion, to support Cytokinetics' corporate, research and development activities. Cytokinetics previously entered into a similar transaction with Kingsbridge in October 2005 and has drawn down all of the shares available under the 2005 CEFF.
